Stability Indicating LC-DAD Method for Determination of Nadifloxacin and Characterization of Its Degradation Products by LC–ESI–MS/MS
- 117 Downloads
Nadifloxacin, a second generation fluoroquinolone, is a topical antibiotic prescribed for acne vulgaris. For any drug, understanding the stability profile is of vital significance as it correlates with the safety and potency of the drug. In the present study, the degradation behaviour of nadifloxacin was studied under different forced degradation conditions. The drug was subjected to acidic, basic, neutral, thermal, photolytic and reduction degradation conditions to evaluate its intrinsic stability. The forced degradation study showed extensive degradation under acidic and reduction conditions, with the formation of nine degradants. A RP-HPLC gradient method was developed for the separation of nadifloxacin and its degradants on a Kromasil C18 (250 mm × 4.6 mm, 5 µm) HPLC column, using ammonium acetate pH 4.5 and acetonitrile as mobile phase. The developed HPLC method has been validated as per ICH guidelines for specificity, linearity, accuracy, LOD and LOQ, precision and robustness. LC–ESI–MS n helped in structural elucidation of degradants and a degradation pathway for nadifloxacin has been proposed. The developed HPLC method can thus be employed as stability indicating method for routine quality control analysis of the drug in bulk samples.
KeywordsHigh performance liquid chromatography Nadifloxacin Forced degradation Degradation products LC–MS
The authors are thankful to Wockhardt research centre, Aurangabad for providing gift sample of nadifloxacin to conduct this study.
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.FDA Guidance for Industry (2000) Analytical Procedures and Methods ValidationGoogle Scholar
- 3.Murthy AR, Babu KR, Vekariya NA (2014) Int J Pharm Pharm Sci 6(9):344–346Google Scholar
- 4.Devhadrao N, Bansode A, Yeole R (2014) Int J Pharm Clin Res 6(1):63–67Google Scholar
- 5.Sharma SD, Singh G (2012) Adv Anal Chem 2(4):25–31Google Scholar
- 6.Patel KK, Bendale A, Luhar SV, Narkhede SV (2016) J Pharm Sci Biosci Res 6(3):276–282Google Scholar
- 7.Kumar A, Sinha S, Agarwal SP, Ali J, Ahuja A (2010) J Food Drug Anal 18(5):358–365Google Scholar
- 8.Nanda RK, Kulkarni AA, Ranjane MN, Ranjane PN (2010) Res J Top Cosmet Sci 1(1):25–29Google Scholar
- 9.Kulkarni AA, Nanda RK, Ranjane MN, Ranjane PN (2010) Der Pharma Chemica 2(3):25–30Google Scholar
- 10.Kalantre UL, Pishwikar SA (2012) Int J PharmTech Res 4:1575–1580Google Scholar
- 11.El-Shal MA, Attia AK, Abdulla SA (2013) J Adv Sci Res 4(2):25–30Google Scholar
- 12.ICH guideline (2000) Q1B photostability testing on new drug substances and products. In: International conference on harmonization. IFPMA, Geneva, SwitzerlandGoogle Scholar
- 13.ICH guideline (2005) Q2 (R1): validation of analytical procedures: text and methodology. In: International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, 2005. IFPMA, Geneva, SwitzerlandGoogle Scholar
- 14.Kumar A, Bhashkar B, Bhavsar J (2016) J Chem Pharm Res 8:609–613Google Scholar
- 17.Cazedey EC, Garag S, Salgado HRN (2013) Int J Sci 2:11–20Google Scholar
- 19.European Pharmacopoeia 9.0. volume II, Ciprofloxacin hydrochloride (2017): 2088–2089Google Scholar